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Colon cancer is a leading cause of morbidity and mortality world-
wide. An anticipated 101 340 Americans will be diagnosed with 
colon cancer in 2011, about one-third of whom will have stage III, 
or node-positive, disease (1,2). Surgery is the mainstay of curative 
therapy for stage III colon cancer. Surgery alone, however, results 
in an unacceptably low 5-year disease-free survival of 15%–50% 
depending on substage (3). During 1990–2004, post-surgical adju-
vant chemotherapy with leucovorin-modulated fluorouracil (here-
after 5-FU) was the standard of care for stage III colon cancer 
based on a 26% relative reduction in mortality compared with 
surgery alone (3,4). In 2004, the Multicenter International Study 
of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant 
Treatment of Colon Cancer (MOSAIC) trial reported that the 
addition of oxaliplatin to 5-FU provided 23% further improve-
ment in relative disease-free survival and 4% absolute improve-
ment in 6-year overall survival in stage III colon cancer (5,6). The 
National Surgical Adjuvant Breast and Bowel Project (NSABP) 
C-07 trial confirmed this finding (7), making adjuvant therapy 
with 5-FU and oxaliplatin the new standard for patients with 
resected stage III colon cancer.
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 Background The addition of oxaliplatin to adjuvant 5-fluorouracil (5-FU) improves survival of patients with stage III colon 
cancer in randomized clinical trials (RCTs). However, RCT participants are younger, healthier, and less racially 
diverse than the general cancer population. Thus, the benefit of oxaliplatin outside RCTs is uncertain.
 Subjects and Methods Patients younger than 75 years with stage III colon cancer who received chemotherapy within 120 days of sur-
gical resection were identified from five observational data sources—the Surveillance, Epidemiology, and End 
Results registry linked to Medicare claims (SEER–Medicare), the New York State Cancer Registry (NYSCR) linked 
to Medicaid and Medicare claims, the National Comprehensive Cancer Network (NCCN) Outcomes Database, 
and the Cancer Care Outcomes Research & Surveillance Consortium (CanCORS). Overall survival (OS) was 
compared among patients treated with oxaliplatin vs non–oxaliplatin-containing adjuvant chemotherapy. 
Overall survival for 4060 patients diagnosed during 2004–2009 was compared with pooled data from five RCTs 
(the Adjuvant Colon Cancer ENdpoinTs [ACCENT] group, n = 8292). Datasets were juxtaposed but not combined 
using Kaplan–Meier curves. Covariate and propensity score adjusted proportional hazards models were used to 
calculate adjusted survival hazard ratios (HR). Stratified analyses examined effect modifiers. All statistical tests 
were two-sided.
 Results The survival advantage associated with the addition of oxaliplatin to adjuvant 5-FU was evident across diverse 
practice settings (3-year OS: RCTs, 86% [n = 1273]; SEER–Medicare, 80% [n = 1152]; CanCORS, 88% [n = 129]; 
NYSCR–Medicaid, 82% [n = 54]; NYSCR–Medicare, 79% [n = 180]; and NCCN, 86% [n = 438]). A statistically sig-
nificant improvement in 3-year overall survival was seen in the largest cohort, SEER–Medicare, and in the 
NYSCR–Medicare cohort (non–oxaliplatin-containing vs oxaliplatin-containing adjuvant therapy, adjusted HR of 
death: pooled RCTs: HR = 0.80, 95% CI = 0.70 to 0.92, P = .002; SEER–Medicare: HR = 0.70, 95% CI = 0.60 to 0.82, 
P < .001; NYSCR–Medicare patients aged ≥65 years: HR = 0.58, 95% CI = 0.38 to 0.90, P = .02). The association 
between oxaliplatin treatment and better survival was maintained in older and minority group patients, as well 
as those with higher comorbidity.
 Conclusion The addition of oxaliplatin to 5-FU appears to be associated with better survival among patients receiving adju-
vant colon cancer treatment in the community.
  J Natl Cancer Inst 2012;104:211–227
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The addition of oxaliplatin to 5-FU unequivocally improves 
outcomes of patients enrolled in RCTs; however, fewer than 2% 
of patients with incident cancer enroll in National Cancer Institute 
trials (8). The patient populations in clinical trials, including 
MOSAIC and C-07, are substantially younger, healthier, and less 
racially and/or ethnically diverse than the general population of 
cancer patients. In addition, dosing and follow-up are defined in 
trials but are at the discretion of the treating physician in routine 
practice. Because oxaliplatin increases toxicity, specifically nausea, 
vomiting, neutropenia, and peripheral neuropathy (5), variations in 
dosing might be expected to alter tolerance and drug delivery and 
thus attenuate the benefit of adjuvant oxaliplatin in community 
settings. Given these potential differences, it is critical to under-
stand the community-based effectiveness of adjuvant chemo-
therapy. We sought to assess the benefit of adding oxaliplatin to 
5-FU for stage III colon cancer in patients treated in the commu-
nity (effectiveness) and to compare that with oxaliplatin benefit in 
phase III RCTs (efficacy). To that end, we compared overall sur-
vival of patients treated with oxaliplatin-containing adjuvant che-
motherapy with overall survival of patients treated with 
non–oxaliplatin-containing regimens in effectiveness samples 
drawn from five observational cohorts and an efficacy sample 
CONTEXT AND CAVEATS
Prior knowledge
Randomized controlled trials have demonstrated that oxaliplatin-
containing adjuvant therapy improves the survival of patients with 
stage III colon cancer. However, it is not known whether this 
therapy improves survival to the same extent in cancer patients in 
the general population.
Study design
The overall survival of 4060 patients treated with oxaliplatin-containing 
vs non–oxaliplatin-containing adjuvant chemotherapy was assessed 
from five observational data sources and compared with pooled 
data from five randomized controlled trials.
Contribution
The use of oxaliplatin-containing adjuvant therapy was associated 
with a consistent pattern of improved survival across the diverse 
practice settings represented by the five cohorts of stage III colon 
cancer patients, including older and minority group patients and 
those with higher comorbidity.
Implications
The addition of oxaliplatin to adjuvant therapies for stage III colon 
cancer shown to confer a survival advantage by randomized con-
trolled trials has proven to be equally beneficial in the more diverse 
therapeutic settings in the general population.
Limitations
The small sample sizes of racial and ethnic minorities limited the 
precision of the hazard ratio estimates. Different follow-up times 
in the different cohorts precluded a unified interpretation across 
all cohorts. The potential for confounding based on patient se-
lection as a substantial cause of improved survival in oxaliplatin-
treated patients could not be eliminated.
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Effectiveness samples came from the following sources: 
Surveillance, Epidemiology, and End Results registry linked to 
Medicare claims (SEER–Medicare); the New York State Cancer 
Registry (NYSCR) linked to Medicaid and Medicare claims; the 
National Comprehensive Cancer Network (NCCN) Outcomes 
Database; and the Cancer Care Outcomes Research & Surveillance 
Consortium (CanCORS). The efficacy sample was drawn from the 
Adjuvant Colon Cancer ENdpoinTs (ACCENT) group. This 
study was approved by the Institutional Review Boards at the 
University of North Carolina (IRB 09-0764); the Brigham and 
Women’s Hospital/Dana-Farber Cancer Institute (IRB 08-338); 
and the Mayo Clinic (IRB 531-04, 120-2005).
Effectiveness Samples. The National Cancer Institute (NCI) 
SEER program of cancer registries collects data on incident 
cancer cases from registries covering 26% of the US population. 
Linkage of case patients to their corresponding Medicare claims 
allows investigation of treatment and outcomes (9,10). A novel 
linkage between the NYSCR and Medicaid and Medicare claims 
captures information on incident cancer case patients diagnosed 
in New York State. The NCCN Outcomes Database comprises 
prospectively abstracted information for incident colorectal 
cancers treated at eight NCI-designated comprehensive cancer 
centers (11,12). CanCORS is a population-based cohort study 
of patients with newly diagnosed colorectal cancer in four geo-
graphical regions, five large health maintenance organizations, 
and 15 Veterans Administration hospitals. Minorities were 
oversampled, and information was gathered through medical 
records abstraction and patient and provider surveys (13,14). 
There is potential overlap between effectiveness cohorts in select 
geographical regions; however, confidentiality restrictions 
precluded our ability to determine the extent of this potential 
overlap. Because the Food and Drug Administration approved 
oxaliplatin for stage III colon cancer in 2004, case patients diag-
nosed in 2004 or later were included.
Efficacy Sample. ACCENT contains individual patient data from 
21 phase III adjuvant colon cancer chemotherapy trials during 
1977–2008. For a contemporary comparison, only trials enrolling 
patients in 1999 and later for which follow-up data were complete 
were included. Five RCTs with a 5-FU control arm met these 
criteria. The experimental arms consisted of capecitabine (XACT), 
5-FU/irinotecan combinations (PETACC-3, C89803), and 
oxaliplatin/5-FU combinations (MOSAIC, C-07) (Table 1) 
(5,7,15–17).
Sample Eligibility
RCTs have included too few patients older than 75 years to make 
robust conclusions about oxaliplatin’s efficacy in older patients. 
Therefore, this analysis is restricted to patients younger than 75 years 
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for whom RCTs compellingly demonstrate oxaliplatin benefit. All 
patients in all samples had histologically confirmed stage III ade-
nocarcinoma of the colon (not rectum) resected within 90 days of 
diagnosis and received adjuvant chemotherapy within 120 days of 
resection (Figure 1). To assure complete claims information, 
patients in SEER–Medicare and NYSCR–Medicare were excluded 
if enrolled in a health maintenance organization or not continu-
ously enrolled in both Medicare Parts A and B in the 6 months 
following diagnosis. To facilitate interpretation of the NYSCR 
with regard to dual Medicare/Medicaid eligibility, the cohort was 
divided into Medicaid patients younger than 65 years (32% of 
whom were also enrolled in Medicare) and Medicare patients who 
were at least 65 years of age (28% of whom were also enrolled in 
Medicaid).
Treatment Ascertainment
Two treatment groups were compared—those receiving oxaliplatin-
containing chemotherapy and those receiving non–oxaliplatin-
containing chemotherapy. In the effectiveness sample, the 
oxaliplatin group included patients with any claim/record of 
oxaliplatin within 30 days of their first chemotherapy dose. The 
non-oxaliplatin group comprised all other patients, including those 
who received capecitabine (16–20). In the efficacy sample the 
oxaliplatin group comprised the oxaliplatin/5-FU arms of C-07 


















Age, y       
 <50 270 (14) 476 (22) 237 (19) 185 (21) 194 (23) 118 (17) 109 (16)
 50–64 893 (45) 1090 (48) 515 (42) 393 (45) 395 (46) 330 (49) 327 (49)
 65–69 422 (21) 421 (19) 193 (16) 142 (16) 130 (15) 133 (20) 140 (21)
 70–74 353 (18) 265 (12) 188 (15) 98 (11) 97 (11) 90 (13) 88 (13)
 75–79 41 (2) 12 (1) 83 (7) 42 (5) 43 (5) 4 (1) 8 (1)
 80–84 2 (<1) 0 (0) 19 (2) 10 (1) 3 (<1) 0 (0) 0 (0)
 ≥85 0 (0) 0 (0) 3 (<1) 1 (<1) 0 (0) 0 (0) 0 (0)
Sex       
 Women 910 (46) 1029 (45) 550 (44) 384 (44) 381 (44) 322 (48) 299 (44)
 Men 1072 (54) 1235 (55) 688 (56) 487 (56) 481 (56) 353 (52) 373 (56)
Race       
 White Imputed Imputed 1098 (89) 761 (87) 731 (85) 662 (98) 647 (96)
 Black — — 85 (7) 54 (6) 61 (7) 3 (<1) 7 (1)
 Asian — — 14 (1) 26 (3) 30 (3) 8 (1) 14 (2)
 Other — — 41 (3) 30 (3) 40 (5) 2 (<1) 4 (1)
Performance status       
 0 Imputed Imputed 923 (75) 730 (84) 724 (84) 583 (86) 570 (85)
 1 — — 304 (25) 140 (16) 136 (16) 89 (13) 100 (15)
 2 — — 7 (1) 1 (<1) 2 (<1) 3 (<1) 2 (<1)
AJCC T stage       
 T1 18 (1) 44 (2) 43 (3) 37 (4) 30 (3) 8 (1) 6 (1)
 T2 182 (9) 149 (7) 114 (9) 122 (14) 104 (12) 54 (8) 51 (8)
 T3 1506 (76) 1720 (76) 971 (79) 647 (75) 672 (78) 491 (73) 486 (72)
 T4 276 (14) 349 (15) 103 (8) 61 (7) 54 (6) 121 (18) 129 (19)
AJCC N stage       
 N1 1389 (70) 1469 (65) 789 (64) 559 (64) 550 (64) 443 (66) 443 (66)
 N2 593 (30) 795 (35) 449 (36) 312 (36) 312 (36) 232 (34) 229 (34)
Year of diagnosis       
 1998 14 (1) 0 (0) 0 (0) 0 (0) 0 (0) 3 (<1) 4 (1)
 1999 528 (27) 5 (<1) 136 (11) 0 (0) 0 (0) 276 (41) 275 (41)
 2000 831 (42) 302 (13) 653 (53) 225 (26) 211 (24) 377 (56) 374 (56)
 2001 609 (31) 1436 (63) 449 (36) 294 (34) 299 (35) 19 (3) 19 (3)
 2002 0 (0) 521 (23) 0 (0) 352 (40) 352 (41) 0 (0) 0 (0)
* This table includes all patients enrolled on these trials. Only patients younger than 75 years were included as the Efficacy cohort of this study.  
AJCC = American Joint Committee on Cancer; FLOX = 5-FU, leucovorin, oxaliplatin with 5-FU given as a bolus; FOLFOX = 5-FU, leucovorin, oxaliplatin 
with 5-FU given as both a bolus and continuous infusion; MOSAIC = Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant 
Treatment of Colon Cancer; N = Node; PETACC3 = Pan-European Trial Adjuvant Colon Cancer-3; T = Tumor; X-ACT = Xeloda in Adjuvant Colon Cancer 
Therapy; 5-FU = 5-Fluorouracil.
† Non-oxaliplatin arms.
‡ Performance status is estimated by Eastern Cooperative Oncology Group except MOSAIC, which used Karnofsky performance status. In MOSAIC, the 
Karnofsky performance status was converted to Eastern Cooperative Oncology Group using the following: performance status 0 = 80–100; 1 = 60–70;  
2 = <60.
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(n = 862) and MOSAIC (n = 672). The 5-FU arms of C-07 and 
MOSAIC and all arms of the other studies comprised the non-
oxaliplatin group.
Statistical Analysis
Covariates. Data on age (measured continuously in all cohorts 
except CanCORS where categories were ages 21–49, 50–64, 65–
69, and 70–74 years), sex, race (white, black, Asian, Latino, other) 
tumor substage (IIIA, IIIB, IIIC, III not otherwise specified), 
tumor grade (well or moderately differentiated, poorly or undiffer-
entiated, differentiation unknown), and year of diagnosis (2004–
2009) were available in all effectiveness samples. Income (quantiles) 
based on zip code or census tract residence was available for SEER–
Medicare, NCCN, and NYSCR; CanCORS contains individual 
estimates (>$60 000; $40 000–$60 000; $20 000–$40 000; <$20 000). 
Comorbidity was measured using the Charlson Comorbidity Index 
(CCI) in NCCN, its Deyo modification in NYSCR, and its Deyo-
Klabunde modification in SEER–Medicare (21–23). Comorbidity 
Figure 1. Effectiveness cohort assembly. 
CanCORS = Cancer Care Outcomes Research & 
Surveillance Consortium; NCCN = National 
Comprehensive Cancer Network Outcomes 
Database; NYSCR = New York State Cancer 
Registry; SEER = Surveillance, Epidemiology, 
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in CanCORS was measured using the Adult Comorbidity 
Evaluation (ACE)-27 index (24,25). Income and comorbidity, 
important covariates estimated differently in each sample, were 
retained in statistical analyses.
For ACCENT, age, sex, substage, and year of trial enrollment 
were available on all patients. Individual patient performance 
status and race were not available on all patients; missing data 
were imputed based on available clinical variables as previously 
reported (n = 4246) (3,26,27). Because 97% of patients enrolled 
in XACT and the overwhelming majority in PETACC-3 
were white, all XACT and PETACC-3 patients were assumed to 
be white.
Overall Survival. Overall survival in the effectiveness cohorts was 
measured from 30 days after surgery. This anchor date was selected 
because it could be reliably ascertained in the effectiveness datasets 
and is a comparable start point to clinical trial randomization date. 
Overall survival in the efficacy cohort was measured from time 
of random assignment to death from any cause. Because of short 
follow-up in most cohorts, 3-year rather than 5-year overall 
survival is reported.
In SEER–Medicare, NYSCR, and NCCN, vital status was 
ascertained through the National Death Index. For CanCORS, 
each participating site updated vital status with censoring at the 
time of each update.
Given their heterogeneity, effectiveness data were not 
combined but juxtaposed after applying consistent inclusion criteria 
and covariate specifications. Within each effectiveness cohort, 
univariate and multivariable logistic regression were used to assess 
the associations among covariates and oxaliplatin receipt. Next, 
overall survival of treatment groups was compared descriptively 
with Kaplan–Meier survival estimates. Cox proportional hazards 
models were used to calculate unadjusted and adjusted hazard 
ratios of survival. The assumption of proportionality was tested 
using the ASSESS option of PHREG in SAS (SAS v9.2; SAS 
Institute, Cary, NC). Survival in each treatment group was 
compared within subgroups to examine whether key covariates 
modified the effect of oxaliplatin. Sample size constraints precluded 
formal interaction testing. Adjusted proportional hazards models 
were also performed for the efficacy cohorts. Analyses were 
conducted with SAS version 9.2 (SAS Institute).
A propensity score analysis compared survival of treatment 
groups within a common range of risk factors for outcome in 
effectiveness cohorts. Using the same covariates as the propor-
tional hazards model, we estimated the likelihood of oxaliplatin 
receipt (the propensity score) for each patient (28). Patients 
with the highest and lowest propensity for oxaliplatin without 
an overlapping patient of similar propensity in the other 
treatment group were omitted to create cohorts with overlap-
ping propensity score distributions. Overall survival of treat-
ment groups was compared within propensity score quintiles. 
Because there was no clear trend of differential treatment 
effect by quintile, a propensity score–adjusted proportional 
hazards model was used to calculate the survival hazard ratio. 
Disease-free survival was not evaluated because it could not be 




A total of 4060 patients were in the effectiveness sample and 8292 
patients in the efficacy sample. As expected from the differences in 
sample acquisition, there were differences in the distribution of age 
and race among cohorts (Table 2). Similar proportions of patients 
across practice settings in the effectiveness sample had serious 
comorbidity as defined by CCI (≥2) or ACE-27 (severe) comorbid 
disease (Table 2), categories shown to have comparable hazards of 
death (29).
Oxaliplatin Receipt in the Community
The proportion of patients treated with oxaliplatin varied consider-
ably: 59% in SEER–Medicare; 54% in CanCORS; 23% in NYSCR–
Medicaid; 51% in NYSCR–Medicare; and 94% in NCCN. Except 
in NCCN where the overwhelming majority of patients received 
oxaliplatin, year of diagnosis was strongly associated with oxalipla-
tin use, which increased substantially between 2004 and 2007 
(Table 3).
The use of oxaliplatin decreased with advancing age. Among 
patients aged 70–74 years, 53% in SEER–Medicare, 37% in 
CanCORS, and 48% in NYSCR–Medicare received oxaliplatin; 
these rates were lower than for patients aged 65–69 years (eg, 
SEER–Medicare adjusted OR = 0.67, 95% CI = 0.56 to 0.81). 
Although 82% of 70- to 74-year-old patients treated at NCCN 
centers received oxaliplatin, this was still lower than the rate for 
65- to 69-year-old patients (96%). Oxaliplatin use was similarly 
low in patients with extensive comorbidity.
The association between race and oxaliplatin receipt was not 
uniform. In CanCORS and NYSCR–Medicaid, there was minimal 
difference in likelihood of oxaliplatin use between blacks and 
whites, whereas in NCCN, SEER–Medicare, and NYSCR–
Medicare, black patients received less oxaliplatin than whites, a 
difference that was substantial in both Medicare populations 
(eg, NYSCR–Medicare 36% vs 54%, OR = 0.44, 95% CI = 0.23 
to 0.83).
Effect of Oxaliplatin on Survival
Three-year survival was superior for patients treated with oxaliplatin-
containing chemotherapy across all cohorts (Figure 2, A–G and 
Table 4). In the efficacy sample, 3-year overall survival of oxaliplatin-
treated patients was 86% (1273 patients), a 4% absolute and a 20% 
relative improvement in survival compared with non–oxaliplatin-
treated patients (adjusted HR of death = 0.80, 95% CI = 0.70 to 
0.92, P = .002; Tables 4 and 5). Three-year overall survival of 
oxaliplatin-treated patients was remarkably similar in the effective-
ness cohorts: 80% (1152) SEER–Medicare, 88% (129) CanCORS, 
82% (54) NYSCR–Medicaid, 79% (180) NYSCR–Medicare, and 
86% (438) NCCN.
Adjusting for differences in patient and tumor characteristics 
between treatment arms, the survival HR point estimates of all 
effectiveness cohorts showed at least as much reduction in the rate 
of death from oxaliplatin treatment as the efficacy cohort (Table 4), 
although the 95% confidence interval crossed 1.0 in all but SEER–
Medicare (HR of death = 0.70, 95% CI = 0.60 to 0.82, P < .001) and 
NYSCR–Medicare (HR of death = 0.58, 95% CI = 0.38 to 0.90, 
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Non-oxaliplatin, n (%) 6812 (82) 1013(41) 125 (46) 224 (77) 218 (49) 33 (6)
Oxaliplatin, n (%) 1480 (18) 1445(59) 147 (54) 66 (23) 228 (51) 561 (94)
Age, y      
 Median years (range) 60 (17–74) 69(27–74) ‡ 54 (25–64) 69 (65–74) 56 (19–74)
  <50 1589 (19) 47(2) 37 (14) 101 (35) — 171 (29)
  50–64 3943 (48) 252(10) 138 (51) 189 (65) — 281 (47)
  65–69 1581 (19) 1136(46) 51 (19) — 225 (50) 80 (13)
  70–74 1179 (14) 1023(42) 46 (17) — 221 (50) 62 (10)
Sex, n (%)      
 Women 3751 (45) 1279(52) 97 (36) 139 (48) 237 (53) 311 (52)
 Men 4541 (55) 1179(48) 175 (64) 151 (52) 209 (47) 283 (48)
Race, n (%)§      
 White 3697 (90) 1992(81) 191 (70) 165 (57) 364 (82) 456 (77)
 Black 201 (5) 275(11) 47 (17) 90 (31) 59 (13) 71 (12)
 Asian 90 (2) 76(3) 12 (4) 31 (11) 19 (4) 48 (8)
 Other 114 (3) 115(5) 22 (8) ǁ ǁ 19 (3)
Latino      
 Yes NA 155(6) 26 (10) 74 (26) 26 (6) 38 (6)
 No — 2303(94) 246 (90) 216 (74) 420 (94) 512 (86)
 Unknown —  —   44 (7)
CCI, n (%)¶      
 0 NA 2065(84) NA 199 (69) 336 (75) 447 (75)
 1 — 245(10) — 41 (14) 67 (15) 87 (15)
 ≥2 — 148(6) — 28 (10) 43 (10) 60 (10)
 Unknown —  — 22 (8)  —
ACE-27, n (%)      
 None NA NA 89 (33) NA NA NA
 Mild — — 104 (38) — — —
 Moderate — — 43 (16) — — —
 Severe — — 36 (13) — — —
Performance status, n (%)      
 0 3373 (82) NA NA NA NA NA
 1 711 (17) — — — — —
 2 14 (<1) — — — — —
Marital status, n (%)      
 Married NA 1487(60) 188 (69) 101 (35) 249 (56) NA
 Single — 274(11) 27 (10) 127 (44) 66 (15) —
 Widowed/divorced — 606(25) 54 (20) 59 (20) 120 (27) —
 Other — 91(4) ǁ ǁ ǁ —
AJCC stage, n (%)      
 IIIA 772 (9) 320(13) 35 (13) 20 (7) 54 (12) 73 (12)
 IIIB 4687 (57) 1330(54) 136 (50) 169 (58) 232 (52) 306 (52)
 IIIC 2820 (34) 806(33) 87 (32) 100 (34) 160 (36) 212 (36)
 III NOS 13 (<1) ǁ 14 (5) ǁ  ǁ
Differentiation, n (%)      
 Well/Moderate NA 1705(69) 199 (73) 196 (68) 293 (66) 412 (69)
 Un/Poor — 686(28) 67 (25) 85 (29) 139 (31) 156 (26)
 Unknown — 67(3) ǁ ǁ 14 (3) 26 (4)
Median income, US dollars#      
 Top quantile NA $185 394 — $106 973 $134 325 $153 918
 Third quantile — $52 828 83 (31%) $47 266 $61 986 $65 367
 Second quantile — $40 203 43 (16%) $35 637 $43 636 $49 958
 First quantile — $29 922 45 (17%) $24 167 $34 663 $36 315
 Bottom quantile — $8,366 49 (18%) $14 ,271 $14 271 $14 642
 Missing —  52 (19%)   —
(Table continues)
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P = .02). The propensity score–adjusted hazard ratios confirmed the 
survival benefit from oxaliplatin seen in the covariate-adjusted 
models (Table 4).
The benefit of oxaliplatin was largely maintained across all 
clinically relevant subgroups examined, although small sample size 
limited the precision of hazard ratio estimates. Oxaliplatin-treated 
patients aged 70–74 years had improved survival in SEER–
Medicare (HR of death = 0.66, 95% CI = 0.52 to 0.84) and 
NYSCR–Medicare (HR of death = 0.62, 95% CI = 0.36 to 1.07), 
but not in CanCORS (Table 4). Oxaliplatin benefit was also 
seen in patients with CCI of at least 2 in SEER–Medicare. In three 
effectiveness cohorts, black patients derived similar or greater 
benefit from oxaliplatin than whites, although analysis of all racial/
ethnic minorities was limited by small sample size.
Discussion
In this study, we found that the use of oxaliplatin-containing adjuvant 
therapy was associated with a consistent pattern of improved 
survival across the diverse practice settings represented by the 
effectiveness cohorts of stage III colon cancer patients, with a 
statistically significant improvement in the largest cohort, SEER–
Medicare, and the NYSCR–Medicare cohort. The survival advantage 
was maintained in older, sicker, and minority group patients.
In 1990, in the wake of multiple positive RCTs, adjuvant 5-FU 
became the standard of care for patients with resected stage III 
colon cancer (4). In 2004, the addition of oxaliplatin was shown to 
further improve disease-free survival and subsequently overall 
survival (5–7). The oxaliplatin/5-FU combination, however, has a 
greater risk of severe cytopenias, nausea and vomiting, diarrhea, 
and peripheral neuropathy than 5-FU alone (5,7). In light of these 
toxic effects, which confer greater risk to oxaliplatin-treated 
patients, should the effectiveness of oxaliplatin be attenuated in 
the community, routine use of adjuvant oxaliplatin for very small 
reductions in mortality might not be warranted. To investigate the 
community effectiveness of oxaliplatin in stage III colon cancer, 
we assembled five observational datasets from diverse treatment 
settings to compare oxaliplatin’s effectiveness to the efficacy demon-
strated in randomized phase III trials. To mirror the trial cohorts, 
we restricted our analyses to patients diagnosed before age 75 years.
The use of oxaliplatin-containing chemotherapy did improve 
survival in these effectiveness cohorts notable for their diversity, 
including patients cared for across the spectrum of treatment 


















Diagnosis year, n (%)      
 1998 20 (<1) — — — — —
 1999 1195 (14) — — — — —
 2000 2854 (34) — — — — —
 2001 3034 (37) — — — — —
 2002 1189 (14) — — — — —
 2003 — — — — — —
 2004 — 690(28) 220 (81) 97 (33) 163 (37) —
 2005 — 612(25) 52 (19) 100 (34) 161 (36) 72 (12)
 2006 — 576(23) — 93 (32) 122 (27) 143 (24)
 2007 — 580(24) — — — 133 (22)
 2008 — — — — — 159 (26)
 2009 — — — — — 87 (15)
Median time from surgery to  
  first chemo, d (range)
NA 44 (0–120) 43 (0–115) 39 (0–118) 47 (9–120) 46 (20–116)
Median FU time, d (range) ** 1218 (14–2157) 1479 (90–2305) 773 (35–1418) 782 (1–1418) 608 (120–1588)
* ACCENT = Adjuvant Colon Cancer End Points Group; ACE-27 = Adult Comorbidity Evaluation-27; AJCC = American Joint Committee on Cancer; CCI = Charlson 
Comorbidity Index; CanCORS = Cancer Care Outcomes Research & Surveillance Consortium; N = Node; NA = not available; NCCN = National Comprehensive 
Cancer Network Outcomes Database; NYSCR–Medicaid = New York State Cancer Registry linked to Medicaid claims; NYSCR–Medicare = New York State 
Cancer Registry linked to Medicare claims; SEER–Medicare = Surveillance Epidemiology and End Results registry linked to Medicare claims; T = Tumor.
† Patients included in the column titled “NYSCR–Medicaid <65 y, N = 290” are all patients less than 65 years of age who have continuous Medicaid enrollment for 
6 months from diagnosis. Thirty-two percent of the patients included here are less than 65 years of age with enrollment in Medicaid and Medicare. Patients in-
cluded in the column titled “NYSCR–Medicare ≥65 y, N = 446” are all patients 65 years of age and older that have continuous Medicare enrollment for 6 months 
from diagnosis. Twenty-eight percent of the patients included here are 65 years of age or older with enrollment in Medicare and Medicaid.
‡ Only categorical data for age are available for CanCORS, and no median can be reported.
§ Race and ethnicity: In NYSCR, Asian patients are included with “other” because of small numbers. Latino ethnicity is not separately available in ACCENT.
ǁ Comorbidity: CanCORS reports comorbidity using the ACE-27, NCCN, the CCI, NYSCR, the Deyo modification of the CCI, and SEER–Medicare, Deyo-Klabunde 
modification of the CCI. ACCENT contains performance status only which was imputed for 4246 patients using multiple imputation based on age, sex, race, 
treatment, and substage.
¶ N < 11. Value omitted to ensure patient confidentiality.
# Income was measured categorically in CanCORS: >$60 000; $40 000–$60 000; $20 000–$40 000; <$20 000.
** Median follow-up for all studies was greater than 5 years.
Table 2 (Continued).
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oncology groups, community oncology practices, and Veterans 
Administration hospitals. Despite including patients from a wide 
array of treatment settings, 3-year survival was very similar in 
oxaliplatin-treated patients in all effectiveness cohorts and the 
efficacy cohort trial patients. After adjusting for key factors related 
to treatment selection and survival, the relative reduction in death 
rates from the addition of oxaliplatin in all effectiveness cohorts was 
comparable with the 20% relative reduction seen in the efficacy 
data and the MOSAIC trial and the 13% relative reduction in death 
from capecitabine/oxaliplatin compared with 5-FU recently reported 
by the XELOXA trial (6,30). The relative reductions in mortality 
were more profound in most effectiveness cohorts than the efficacy 
cohort, likely related to unmeasured confounding such as frailty 
that led patients treated in the community to forego oxaliplatin and 
thereby made the non-oxaliplatin group a more frail population.
Oxaliplatin use was associated with statistically significantly 
improved survival in the oldest age group investigated, 70–74 years, 
in the SEER–Medicare cohort, with a trend toward improved 
survival in NYSCR–Medicare. Older CanCORS patients did not 
benefit from oxaliplatin, although there was no suggestion of 
harm. Although adjuvant 5-FU clearly improves survival among 
older patients, the role of combination chemotherapy has been an 
area of concern (14,31–35). In the case of oxaliplatin/5-FU combi-
nations, two publications (36,37) have suggested that older patients 
benefit from the addition of oxaliplatin, although a recent pooled 
analysis suggested oxaliplatin use might be harmful in patients 
older than 70 years (HR of death = 1.18, 95% CI = 0.90 to 1.57) 
(38). Although our findings do not support the notion of harm, 
only about half of this age group received oxaliplatin; thus, it is 
uncertain from this analysis whether expanding the use of oxaliplatin 
to the entire group of chemotherapy-treated patients aged 65–74 
years would be safe or effective.
We also examined the comparative treatment effect within clini-
cally relevant patient subgroups. Many of these subgroups were too 
small to yield precise estimates of oxaliplatin’s effect; however, the 
benefit of oxaliplatin appeared to extend to patients with at least two 
comorbid conditions as defined by CCI in SEER–Medicare and by 
“moderate” comorbidity as defined by the ACE-27. The small 
group of oxaliplatin-treated patients with “severe” comorbidity in 
CanCORS had inferior survival; however, because we limited this 
investigation to patients who survived 30 days from resection and 
received their first dose of chemotherapy within 120 days, most 
patients with major comorbidity were excluded from the analysis.
Subgroup analysis also found that oxaliplatin is associated with 
a similar reduction in death rates in blacks and whites in most 
cohorts, although variation among cohorts merits a more extensive 
examination. The small sample size of all racial and ethnic minorities 
even in this large multi-cohort investigation suggests that efforts 
specifically designed to study the outcomes of minority patients 
with colon cancer are warranted.
This study also had some other limitations besides small sample 
size of racial and ethnic minorities. A multicenter, multi-cohort 
comparative effectiveness project presents a number of challenges 
in the examination and interpretation of observational data from 
multiple sources. For example, different follow-up times among 
cohorts challenged a unified interpretation. In CanCORS, the 
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(continued)
converge around 45 months after which there appears to be no 
survival benefit from oxaliplatin (not shown); this was not the case 
in any other dataset. This convergence at a follow-up time point 
beyond that available in the other cohorts raises the possibility that 
the effect of oxaliplatin over time may not be as robust in the com-
munity as it was in the MOSAIC trial. Unfortunately, the short 
follow-up for most cohorts currently prevents investigation into 
whether oxaliplatin effect attenuates with time.
Our analysis was subject to the limitations of each data source. 
We limited our analyses to overall survival because it was reliably 
and consistently collected for each cohort; however, disease-free 
survival is a more direct indicator of colon cancer recurrence and 
thus failure of adjuvant treatment. Quality of life is another crucial 
metric that likely varies by the type of chemotherapy given. 
Neither disease-free survival nor quality of life could be reliably 
determined across the effectiveness cohorts.
Most importantly, notwithstanding our efforts to assemble 
comparable cohorts and our multivariable models, we could not 
eliminate the potential for confounding based on patient selection 
as a substantial cause of improved survival in oxaliplatin-treated 
patients. We used a traditional proportional hazards model to 
account for known relevant confounders rather than propensity 
score techniques because we found no evidence that subgroups of 
patients received only one of the compared treatments or nonuni-
form treatment effects over the propensity score (39,40). We per-
formed a propensity score analysis to compare treatments among 
patients of similar risk profiles and found minimal differences 
between covariate-adjusted and propensity score–adjusted hazard 
ratios. However, both traditional proportional hazards models and 
propensity score techniques can only account for known measured 
confounders (41,42). Neither can overcome the inability to 
measure critical confounders that influence survival such as func-
tional status. Nevertheless, whereas unmeasured confounding re-
lated to treatment selection is a potential problem in all effectiveness 
cohorts, and the confidence intervals crossed 1.0 in three of five 
cohorts, the consistency of our findings across diverse cohorts with 
jnci.oxfordjournals.org   JNCI | Articles 221
Figure 2. Comparison of Kaplan–Meier survival in 
months by treatment in stage III colon cancer 
patients treated with adjuvant chemotherapy by 
cohort. Error bars indicate 95% confidence inter-
vals at 10-month intervals. Cox proportional haz-
ards models were used to calculate the unadjusted 
hazard ratios (HRs) of death and 95% confidence 
intervals (CIs). Unadjusted hazard ratios were not 
calculated for ACCENT. All statistical tests were 
two-sided. A) All cohorts. Solid line = oxaliplatin; 
Dotted line = non-oxaliplatin. ACCENT shown in 
black; SEER–Medicare, green; CanCORS, red; NYSCR–
Medicare, yellow; NYSCR–Medicaid, purple; 
NCCN, blue. B) ACCENT. C) SEER–Medicare (HR 
of death = 0.74, 95% CI = 0.63 to 0.86, 
P < .001). D) CanCORS (HR of death = 0.68, 95% 
CI = 0.44 to 1.04, P = .07). E) NYSCR–Medicaid 
(HR of death = 0.76, 95% CI = 0.34 to 1.72, P = .51). 
F) NYSCR–Medicare (HR of death = 0.70, 95% 
CI = 0.46 to 1.05, P = .08). G) NCCN (HR of death = 
0.47, 95% CI = 0.18 to 1.20, P = .11). ACCENT = 
Adjuvant Colon Cancer End Points Group; 
CanCORS = Cancer Care Outcomes Research & 
Surveillance Consortium; NYSCR–Medicaid = 
New York State Cancer Registry linked to 
Medicaid claims; NYSCR–Medicare = New York 
State Cancer Registry linked to Medicare 
claims; NCCN = National Comprehensive Cancer 
Network Outcomes Database; SEER–Medicare = 
Surveillance Epidemiology and End Results reg-
istry linked to Medicare claims. *N < 11. Value 
omitted to ensure patient confidentiality. 
different potential for bias suggests that oxaliplatin is not only 
efficacious in the clinical trial setting but also effective.
In summary, our analyses suggest that the benefit of oxaliplatin 
evident in clinical trials appears to manifest in day-to-day practice. 
Physicians and patients should be reassured from our findings that 
oxaliplatin is associated with marginally but consistently superior 
survival for patients diagnosed before age 75 years in community 
settings. Future research should examine the comparative effec-















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































tiveness and safety of oxaliplatin in high-risk subgroups including 
patients older than 75 years, patients with severe comorbidity, and 
racial and ethnic minorities. Systematic methods for the study of 
these groups must be implemented for comparative effectiveness 
research to successfully address their outcomes.
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